Table 4.

Number of Participants with Hospitalization and/or Serious Adverse Events -Total, and by Treatment Arm (ITT Population) including all events reported after randomization through to Day 28

		Randomized Treatment
Event	Total (N=626)	Combination Antivirals (N=314)	Oseltamivir (N=312)
Any Hospitalization	16 (3%)	13 (4%)	3 (1%)
Serious Adverse Events
Any Serious Adverse Events	20 (3%)	14 (4%)	6 (2%)
Respiratory, thoracic and mediastinal disorders	5 (1%)	4 (1%)	1 (<0·5%)
Asthma	2 (<0·5%)	2 (1%)	0 (0%)
Pulmonary oedema	1 (<0·5%)	1 (<0·5%)	0 (0%)
Respiratory distress	1 (<0·5%)	1 (<0·5%)	0 (0%)
Bronchospasm	1 (<0·5%)	0 (0%)	1 (<0·5%)
Gastrointestinal disorders	4 (1%)	4 (1%)	0 (0%)
Diarrhoea	2 (<0·5%)	2 (1%)	0 (0%)
Nausea	1 (<0·5%)	1 (<0·5%)	0 (0%)
Diarrhoea haemorrhagic	1 (<0·5%)	1 (<0·5%)	0 (0%)
Infections and infestations	4 (1%)	3 (1%)	1 (<0·5%)
Pneumonia	2 (<0·5%)	1 (<0·5%)	1 (<0·5%)
Gastroenteritis	1 (<0·5%)	1 (<0·5%)	0 (0%)
Cellulitis	1 (<0·5%)	1 (<0·5%)	0 (0%)
Cardiac disorders	3 (<0·5%)	2 (1%)	1 (<0·5%)
Atrial fibrillation	1 (<0·5%)	1 (<0·5%)	0 (0%)
Cardiac failure	1 (<0·5%)	0 (0%)	1 (<0·5%)
Atrial tachycardia	1 (<0·5%)	1 (<0·5%)	0 (0%)
Psychiatric disorders	2 (<0·5%)	0 (0%)	2 (1%)
Delirium	1 (<0·5%)	0 (0%)	1 (<0·5%)
Personality change	1 (<0·5%)	0 (0%)	1 (<0·5%)
Skin and subcutaneous tissue disorders	1 (<0·5%)	1 (<0·5%)	0 (0%)
Diabetic foot	1 (<0·5%)	1 (<0·5%)	0 (0%)
Metabolism and nutrition disorders	1 (<0·5%)	1 (<0·5%)	0 (0%)
Dehydration	1 (<0·5%)	1 (<0·5%)	0 (0%)
Injury, poisoning and procedural complications	1 (<0·5%)	1 (<0·5%)	0 (0%)
Spinal compression fracture	1 (<0·5%)	1 (<0·5%)	0 (0%)
Injury, poisoning and procedural complications	1 (<0·5%)	0 (0%)	1 (<0·5%)
Febrile neutropenia	1 (<0·5%)	0 (0%)	1 (<0·5%)